Facetime with Phil: FDA’s New Position on Off-Label Drug Use

Promoting the use of FDA-approved drugs for unapproved uses may pose a danger to our patients. Join myMatrixx Chief Clinical Officer, Phil Walls, in video three of the four-part Facetime with Phil video blog on off-label drug use, as he encourages and explains how we all can be patient advocates.

BACK TO ALL VIDEOS

OTHER VIDEOS IN THIS SERIES

DEFINING OFF-LABEL DRUG USE OFF-LABEL VS. INVESTIGATIONAL DRUG USE

POTENTIAL IMPACT ON WORKERS’ COMP ARE COMPOUNDS OFF LABEL OR EXPERIMENTAL?

INAPPROPRIATE WARNINGS FOR OPIOIDS